-
Intravenous thrombolysis is safe and effective for the treatment of ischemic stroke in the time window of 3-4.5 hours after the onset of symptoms.
-
Ongoing safety review of tiotropium; raloxifene reduces the risk of endometrial cancer; one-day treatment with famciclovir may be as effective as 3-day treatment with valacyclovir; new Clinical Practice Guideline from the American College of Physicians regarding pharmacologic treatment for low bone density and osteoporosis; FDA Actions.
-
Statins may cause worsening symptoms in patients with myasthenia gravis.
-
Aspirin plus extended-release dipyridamole and clopidogrel are both appropriate options to decrease disability from recurrent stroke; however, telmisartan does not lower risk of suffering a second stroke.
-
Neuromyelitis optica (NMO) may be a unique central nervous system demyelinating disease with distinct clinical and MRI manifestations, as well as different immune and pathological characteristics as compared to multiple sclerosis (MS).
-
Some women with DVT may stop warfarin after six months; Vytorin and cancer; preventing recurrent stroke; and FDA news.
-
The anti-angiogenic monoclonal antibody, bevacizumab, shows great promise in the treatment of malignant gliomas.
-
The Babinski sign continues to be a valid bed-side test for pyramidal tract lesions.
-
Platelet function testing identifies patients who do not respond to antiplatelet therapy and are at increased risk for acute stent thrombosis after neurointerventional procedures.
-